| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥2.1B | ¥0.3B | +674.2% |
| Operating Income | ¥-7.7B | ¥-5.6B | -36.7% |
| Ordinary Income | ¥-7.3B | ¥-6.1B | -20.7% |
| Net Income | ¥-7.4B | ¥-6.1B | -20.4% |
| ROE | -14.7% | -11.1% | - |
FY2026 Q3 results: Revenue 2.1B yen (YoY +674.2%), Operating Income -7.7B yen (YoY -36.7% deterioration), Ordinary Income -7.3B yen (YoY -20.7% deterioration), Net Income -7.4B yen (YoY -20.4% deterioration). Revenue expanded significantly from 0.3B yen in the prior year period, reflecting business scale-up in regenerative medicine products. However, absolute revenue remains small while SG&A expenses of 9.0B yen including R&D costs of 4.5B yen drove operating losses deeper from -5.6B yen to -7.7B yen. Gross profit margin stood at 61.0%, but SG&A expenses represented 433.6% of revenue, resulting in an operating margin of -372.5%. Basic EPS was -89.31 yen compared to -76.58 yen in the prior year. The company maintains substantial cash reserves of 35.7B yen (68.5% of total assets), providing near-term liquidity despite continued operating losses. Full-year guidance projects revenue of 2.1B yen with operating loss of -10.2B yen.
Revenue increased 674.2% YoY from 0.3B yen to 2.1B yen, driven by expansion in regenerative medicine product sales. Cost of sales was 0.8B yen, yielding gross profit of 1.3B yen at a 61.0% margin, indicating favorable product economics at the gross profit level. However, SG&A expenses totaled 9.0B yen (433.6% of revenue), primarily consisting of R&D expenditure of 4.5B yen (215.4% of revenue), which is characteristic of early-stage biotechnology companies investing heavily in pipeline development. The substantial fixed cost base relative to revenue scale resulted in operating loss expanding from -5.6B yen to -7.7B yen, a deterioration of 2.1B yen. Non-operating items contributed a net positive of 0.4B yen, comprising interest income of 0.1B yen and FX gains of 0.1B yen, offset by FX losses of 0.4B yen recorded in non-operating expenses. This narrowed the gap between operating loss and ordinary loss to 0.4B yen. Ordinary loss was -7.3B yen compared to -6.1B yen in the prior year. Income tax expense was minimal at 0.0B yen given the loss position, and NCI net income of -0.1B yen resulted in net loss attributable to owners of parent of -7.4B yen. The deterioration from operating loss to net loss was limited to 0.1B yen (1.4% difference), indicating earnings quality is primarily driven by core operations rather than extraordinary items. This represents a "revenue up / profit down" pattern, where top-line growth occurred but profitability deteriorated due to R&D-heavy cost structure outpacing revenue expansion.
[Profitability] Operating margin -372.5% (deteriorated from -2,169.2% YoY on absolute basis but reflects revenue base expansion), net profit margin -353.6%, ROE -14.7% (negative due to cumulative losses), gross profit margin 61.0% demonstrates product-level profitability potential. [Cash Quality] Cash and deposits 35.7B yen represent 68.5% of total assets, providing short-term liquidity coverage of 28.6x current liabilities (35.7B yen cash vs 1.3B yen current liabilities). Short-term investment securities of 2.2B yen provide additional liquid reserves. Combined cash and short-term investments total 37.9B yen, indicating substantial financial cushion. [Investment Efficiency] Asset turnover 0.04x (well below industry median 0.17x), reflecting early-stage revenue generation relative to asset base. ROIC -52.9% indicates capital is not yet generating positive returns, consistent with pre-commercial biotech profile. [Financial Health] Equity ratio 96.5% (vs industry median 67.8%), current ratio 3,705.8%, debt-to-equity ratio 0.04x. Total liabilities only 1.8B yen against total assets of 52.1B yen, reflecting conservative capital structure with negligible debt. However, retained earnings deficit expanded to -34.8B yen from -27.5B yen YoY, representing cumulative losses that erode shareholder equity over time.
Cash and deposits decreased 4.8B yen YoY from 40.5B yen to 35.7B yen, primarily reflecting operating loss consumption. The company's substantial cash position of 35.7B yen combined with short-term investments of 2.2B yen provides total liquid assets of 37.9B yen, representing 72.7% of total assets and offering 30.3x coverage of current liabilities. This cash reserve provides runway to absorb ongoing operating losses while advancing pipeline development. Trade receivables declined sharply from 1.6B yen to 0.0B yen, indicating either collection of prior period receivables, shift in sales terms to advance payment, or change in revenue recognition timing. Inventories decreased 32.4% from 0.5B yen to 0.3B yen, though inventory turnover days of 138 remain elevated relative to the small revenue base. Working capital remains highly positive at 45.2B yen (current assets 46.4B yen minus current liabilities 1.3B yen), providing substantial operating flexibility. The absence of significant debt obligations (current liabilities only 1.3B yen, non-current liabilities 0.6B yen) indicates financing activities have not required external leverage. Total equity decreased from 55.3B yen to 50.3B yen, driven by the 7.4B yen net loss accumulation, demonstrating that equity capital is funding operations without debt financing.
Ordinary income of -7.3B yen versus operating income of -7.7B yen shows non-operating net contribution of approximately 0.4B yen, representing 5.5% of operating loss. Non-operating income totaled 0.4B yen, comprising interest income of 0.1B yen, FX gains of 0.1B yen, and other income. Non-operating expenses primarily consisted of FX losses of 0.4B yen. The limited gap between operating and ordinary income indicates core business operations drive overall results, with financial and FX activities providing modest offset. Interest income of 0.1B yen relative to cash assets of 35.7B yen implies a yield of approximately 0.3%, consistent with conservative treasury management. The absence of equity method gains, impairment losses, or asset sales indicates clean operational results without non-recurring adjustments. Comprehensive income of -7.7B yen included FX translation adjustment of -0.3B yen, slightly below net income of -7.4B yen. Tax burden coefficient of 0.997 indicates minimal tax impact given loss position. While cash flow statement data is unavailable for detailed operating CF analysis, the substantial cash position relative to operating losses suggests historical equity financing has built reserves to fund the development stage, though ongoing cash consumption warrants monitoring of burn rate against runway.
Full-year guidance projects revenue of 2.1B yen (achievement rate 98.5% through Q3), operating loss of -10.2B yen (Q3 progress 75.5%), ordinary loss of -9.8B yen (Q3 progress 74.9%), and EPS of -119.88 yen. Q3 revenue progress of 98.5% suggests Q4 revenue will be minimal, indicating backend weighting was not anticipated. Operating loss progress of 75.5% through Q3 against full-year guidance of -10.2B yen implies Q4 operating loss of approximately 2.5B yen, representing a quarterly cost run-rate consistent with prior periods. The company revised guidance during the quarter, though specific changes are not detailed. Given Q3 cumulative operating loss of -7.7B yen against full-year guidance of -10.2B yen, the implied Q4 operating loss of -2.5B yen would represent improvement from the Q3 quarterly average of -2.6B yen (assuming even quarterly distribution), suggesting modest cost management. Revenue guidance of 2.1B yen represents 21.0% growth from prior full year, indicating management expects limited incremental revenue in remaining quarter. EPS guidance of -119.88 yen compares to Q3 cumulative EPS of -89.31 yen, implying additional Q4 loss per share of approximately -30.57 yen.
The company maintains zero dividend policy with annual dividend of 0.00 yen and no changes from prior year. Payout ratio is not applicable given net loss position. No share buyback activities were disclosed. The absence of shareholder returns reflects the company's development stage where cash preservation for R&D investment takes priority over capital distribution. With retained earnings deficit of -34.8B yen and ongoing operating losses, dividend initiation would require sustained profitability and positive retained earnings. The substantial cash position of 35.7B yen theoretically provides capacity for distributions, but prudent capital allocation prioritizes funding pipeline development to reach commercial viability. Total return ratio is 0% given no dividends or buybacks.
Commercialization timing risk: As a single-segment regenerative medicine company with revenue of only 2.1B yen against R&D spending of 4.5B yen, delays in product approvals or market adoption directly impact the business model with no diversification buffer. Pipeline dependency creates binary outcomes for valuation.
Operating loss sustainability: Operating loss of 7.7B yen against cash reserves of 35.7B yen provides approximately 4.6 years of runway at current burn rate, but assumes no further revenue growth. Extended time-to-profitability could necessitate additional capital raises with dilution risk, particularly if clinical trial setbacks increase development costs.
Inventory and working capital efficiency: Inventory turnover of 138 days is elevated relative to revenue scale, suggesting potential obsolescence risk or demand forecasting challenges. Combined with accounts receivable elimination (from 1.6B yen to 0.0B yen), working capital management and sales cycle dynamics warrant monitoring for operational effectiveness.
[Industry Position] (Reference - Proprietary Analysis)
The company's financial profile reflects typical early-stage pharmaceutical/biotech characteristics, with performance metrics significantly diverging from industry medians due to pre-commercialization status.
Profitability: Operating margin -372.5% compares to industry median -218.2% (2025-Q3, n=13), indicating higher cost intensity relative to revenue base. ROE -14.7% versus industry median -35.8% appears relatively favorable, but this reflects the company's stronger equity capitalization (96.5% equity ratio vs industry median 67.8%) rather than superior earnings generation. Net profit margin -353.6% versus industry median -216.8% demonstrates below-median profitability.
Efficiency: Asset turnover 0.04x substantially trails industry median 0.17x, indicating less efficient revenue generation from asset base. Inventory turnover of 138 days compares favorably to industry median 282 days, though this reflects limited inventory relative to development-stage operations. Operating working capital cycle cannot be directly compared given zero receivables.
Financial Health: Equity ratio 96.5% significantly exceeds industry median 67.8%, indicating conservative capital structure with minimal leverage. Current ratio 3,705.8% far surpasses industry median 662%, reflecting substantial cash cushion relative to near-term obligations. The company maintains stronger balance sheet liquidity than typical industry peers.
Growth: Revenue growth of 674.2% YoY substantially exceeds industry median -12.5%, though this reflects recovery from very low base rather than sustained commercial traction. Industry comparisons show the company is in line with sector norms for development-stage firms trading growth investment against near-term profitability.
※ Industry: Pharmaceutical (13 companies), Comparison: 2025-Q3 period, Source: Proprietary analysis
Early-stage commercialization trajectory with substantial cash reserves: Revenue expansion of 674.2% YoY demonstrates business model activation, though absolute revenue of 2.1B yen remains small relative to 9.0B yen SG&A base. The company's 35.7B yen cash position (68.5% of assets) and 96.5% equity ratio provide 4-5 years of operating runway at current burn rate, offering financial stability to execute development programs without near-term funding pressure. However, path to profitability requires either significant revenue scale-up or material cost base rationalization.
R&D intensity signals pipeline investment focus: R&D expenditure of 4.5B yen representing 215.4% of revenue substantially exceeds typical pharmaceutical R&D intensity, indicating aggressive pipeline development prioritization over near-term margin optimization. This positions the company as a research-driven asset with valuation dependent on clinical and regulatory milestone achievement rather than current financial returns. The 61.0% gross margin demonstrates product-level economics can support profitable operations once revenue scales sufficiently to absorb fixed R&D infrastructure.
Working capital efficiency inflection: Elimination of trade receivables (1.6B yen to 0.0B yen) and inventory reduction (0.5B yen to 0.3B yen) suggest either shift toward advance payment terms improving cash conversion, or revenue mix change affecting working capital requirements. Combined with 138-day inventory turnover, operational efficiency improvement opportunity exists. Current ratio of 3,705.8% and negligible debt (debt-to-equity 0.04x) provide financial flexibility, though ongoing equity erosion from cumulative losses (retained earnings -34.8B yen) warrants monitoring for potential future dilution if profitability timeline extends.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.